Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Intelligent Bio Solutions Inc. (INBS)
USD2.36
+0.11 (+4.89%)
US NASDAQ Healthcare Medical - Diagnostics & Research
Address
142 West 57th Street 10019
New York City, NY, US
New York City, NY, US
CEO
Harry Simeonidis
Website
gbs.inc
IPO
2020-12-23
CIK 1725430 ISIN US36151G7097
Also trades on
NASDAQ Capital Market · INBS (USD)
NASDAQ Global Market · GBS (USD)
Description
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.36
+0.11 (+4.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
124.0K
Beta
4.18
Float Shares
637.5K
Free Float %
98.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +25.47% | +70.51% | +62.20% | -20.52% | -44.35% | -58.13% | -70.66% | -98.88% | -99.95% | -99.98% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.36
DCF (Unlevered)
0.37
-84.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-8.40
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%-1.9% Q1'26: +45.5% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+68.7% ★ Q1'26: +59.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-342.9% Q1'26: -407.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-341.5% Q1'26: +0.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-502.2% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+65.6% Q1'26: +176.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.03× Q1'26: -0.14× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 1.98M (-100.0%)
|
1.26M
est: 1.75M (-28.2%)
|
3.11M
est: 4.20M (-25.9%)
|
3.05M
est: 11.60M (-73.7%)
|
26.30M
26.30M – 26.30M
+126.7% YoY
|
14.65M
14.65M – 14.65M
-44.3% YoY
|
| EBITDA |
-8.33M
est: -792.0K (-951.3%)
|
-9.47M
est: -700.6K (-1,252.3%)
|
-9.31M
est: -1.68M (-454.1%)
|
-9.45M
est: -4.64M (-103.8%)
|
-10.52M
-10.52M – -10.52M
-126.7% YoY
|
-5.86M
-5.86M – -5.86M
+44.3% YoY
|
| EBIT |
-8.33M
est: -1.19M (-600.9%)
|
-10.44M
est: -1.05M (-893.5%)
|
-10.28M
est: -2.52M (-308.1%)
|
-10.42M
est: -6.96M (-49.8%)
|
-15.78M
-15.78M – -15.78M
-126.7% YoY
|
-8.79M
-8.79M – -8.79M
+44.3% YoY
|
| Net Income |
-8.31M
est: -860.66M (+99.0%)
|
-10.63M
est: -366.41M (+97.1%)
|
-10.16M
est: -19.35M (+47.5%)
|
-10.57M
est: -6.59M (-60.3%)
|
1.85M
1.85M – 1.85M
+128.0% YoY
|
-49.36M
-49.36M – -49.36M
-2,774.3% YoY
|
| SGA |
4.92M
est: 5.93M (-17.0%)
|
8.03M
est: 5.24M (+53.1%)
|
9.26M
est: 12.57M (-26.4%)
|
8.88M
est: 34.73M (-74.4%)
|
78.73M
78.73M – 78.73M
+126.7% YoY
|
43.86M
43.86M – 43.86M
-44.3% YoY
|
| EPS |
-113.30
est: -1,632.00 (+93.1%)
|
-105.80
est: -694.80 (+84.8%)
|
-63.80
est: -36.70 (-73.8%)
|
-20.00
est: -12.50 (-60.0%)
|
3.50
3.50 – 3.50
+128.0% YoY
|
-93.60
-93.60 – -93.60
-2,774.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.58M
OE per share TTM
-14.33
Owner's Yield
-320.85%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
29.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
1.38M
Insider transactions (90d)
0
Beneficial owners (>5%)
19
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jeff Easton | 2.45M | 9.90% | 2.45M | — | 2.45M | — | IN | Delaware | 2023-10-20 | ↗ |
| 2 | Lind Global Fund II LP | 2.45M | 9.90% | 2.45M | — | 2.45M | — | PN | Delaware | 2023-10-20 | ↗ |
| 3 | Lind Global Partners II LLC | 2.45M | 9.90% | 2.45M | — | 2.45M | — | OO | Delaware | 2023-10-20 | ↗ |
| 4 | Alyeska Fund GP, LLC | 420.7K | 9.99% | — | 420.7K | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 5 | Alyeska Investment Group, L.P. | 420.7K | 9.99% | — | 420.7K | — | — | IA | Delaware | 2024-11-14 | ↗ |
| 6 | Anand Parekh | 420.7K | 9.99% | — | 420.7K | — | — | IN | Delaware | 2024-11-14 | ↗ |
| 7 | Michael Bigger | 289.0K | 7.50% | — | — | — | 289.0K | IN | Delaware | 2023-10-04 | ↗ |
| 8 | The Ma-Ran Foundation | 213.3K | 12.30% | 213.3K | — | 213.3K | — | OO | — | 2023-06-01 | ↗ |
| 9 | Foundation | 190.5K | 11.00% | — | 190.5K | — | 190.5K | OO | — | 2023-06-01 | ↗ |
| 10 | Gary W. Rollins | 190.5K | 11.00% | 190.5K | — | 190.5K | — | IN | — | 2023-06-01 | ↗ |
| 11 | Brendan O’Neil | 148.5K | 9.99% | — | 148.5K | — | 148.5K | IN | California, United States | 2023-03-13 | ↗ |
| 12 | Ionic Ventures, LLC | 148.5K | 9.99% | — | 148.5K | — | 148.5K | OO | California, United States | 2023-03-13 | ↗ |
| 13 | Keith Coulston | 148.5K | 9.99% | — | 148.5K | — | 148.5K | IN | California, United States | 2023-03-13 | ↗ |
| 14 | Bigger Capital Fund GP, LLC | 144.5K | 3.70% | — | — | — | 144.5K | OO | Delaware | 2023-10-04 | ↗ |
| 15 | Bigger Capital Fund, LP | 144.5K | 3.70% | — | — | — | 144.5K | PN | Delaware | 2023-10-04 | ↗ |
| 16 | District 2 Capital Fund LP | 144.5K | 3.70% | — | — | — | 144.5K | PN | Delaware | 2023-10-04 | ↗ |
| 17 | District 2 Capital LP | 144.5K | 3.70% | — | — | — | 144.5K | PN | Delaware | 2023-10-04 | ↗ |
| 18 | District 2 GP LLC | 144.5K | 3.70% | — | — | — | 144.5K | OO | Delaware | 2023-10-04 | ↗ |
| 19 | District 2 Holdings LLC | 144.5K | 3.70% | — | — | — | 144.5K | OO | Delaware | 2023-10-04 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
12
+3 vs prev Q
New positions
5
Closed positions
2
Increased
11
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADAR1 CAPITAL MANAGEMENT, LLC | — -426.4K (-100.0%) | — -435.0K (-100.0%) | 0.00% -8.086 pp | 0.00% -0.041 pp | USD— | 2 qtrs SOLD |
| 2 | ALYESKA INVESTMENT GROUP, L.P. | — -673.5K (-100.0%) | — -687.0K (-100.0%) | 0.00% -12.771 pp | 0.00% -0.002 pp | USD— | 8 qtrs SOLD |
| 3 | BANK OF AMERICA CORP /DE/ | — -64.0 (-100.0%) | — -65.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 7 qtrs SOLD |
| 4 | CITIGROUP INC | — -9.3K (-100.0%) | — -9.5K (-100.0%) | 0.00% -0.177 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 5 | CURIO WEALTH, LLC | — -2.0K (-100.0%) | — -2.0K (-100.0%) | 0.00% -0.038 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | — -58.9K (-100.0%) | — -60.0K (-100.0%) | 0.00% -1.116 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 7 | GOLDMAN SACHS GROUP INC | — -12.8K (-100.0%) | — -13.1K (-100.0%) | 0.00% -0.243 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 8 | LPL FINANCIAL LLC | — -25.0K (-100.0%) | — -25.5K (-100.0%) | 0.00% -0.474 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 9 | NATIONAL BANK OF CANADA /FI/ | — -350.0 (-100.0%) | — -354.0 (-100.0%) | 0.00% -0.007 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 10 | NBC SECURITIES, INC. | — -2.6K (-100.0%) | — -2.7K (-100.0%) | 0.00% -0.050 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 11 | VANGUARD GROUP INC | — -97.7K (-100.0%) | — -99.6K (-100.0%) | 0.00% -1.852 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 12 | WARBERG ASSET MANAGEMENT LLC | — -44.7K (-100.0%) | — -45.6K (-100.0%) | 0.00% -0.848 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 14.6K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
81.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+81,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Simeonidis Harry | Officer | A-Award | A | Common Stock | 21,350 | 0.00 | — | 34,540 | D | ↗ |
| 2026-03-18 | Sakiris Spiro Kevin | Officer | A-Award | A | Common Stock | 21,350 | 0.00 | — | 33,981 | D | ↗ |
| 2026-03-18 | Isenberg Jason | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 5,000 | D | ↗ |
| 2026-03-18 | Hurd Jonathan Scott | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 5,006 | D | ↗ |
| 2026-03-18 | Fraser Nicola Marion | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 5,000 | D | ↗ |
| 2026-03-18 | Boyages Steven Constantine | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 5,031 | D | ↗ |
| 2024-09-25 | Simeonidis Harry | Officer | A-Award | A | Common Stock | 40,000 | 0.00 | — | 40,408 | D | ↗ |
| 2024-09-25 | Sakiris Spiro Kevin | Officer | A-Award | A | Common Stock | 34,500 | 0.00 | — | 34,815 | D | ↗ |
| 2024-06-07 | Fraser Nicola Marion | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-20 | Sakiris Spiro Kevin | Officer | X-InTheMoney | A | Common Stock | 9,394 | 6.60 | 62.0K | 19,180 | — | ↗ |
| 2023-10-04 | TOWERS CHRISTOPHER | Director | P-Purchase | A | Common Stock | 9,090 | 0.55 | 5.0K | 9,880 | — | ↗ |
| 2023-10-04 | Sakiris Spiro Kevin | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-01 | Simeonidis Harry | Officer | P-Purchase | A | Common Stock, par value $0.01 per share | 50 | 1.85 | 92.50 | 4,180 | — | ↗ |
| 2023-08-31 | Simeonidis Harry | Officer | P-Purchase | A | Common Stock, par value $0.01 per share | 100 | 1.92 | 192.00 | 4,130 | — | ↗ |
| 2023-05-12 | Ma-Ran Foundation | 10% Owner | — | D | Common stock, par value $0.01 per share | 0 | 0.00 | — | 213,265 | — | ↗ |
| 2023-05-12 | Gary W. Rollins Foundation | 10% Owner | — | D | Common stock, par value $0.01 per share | 0 | 0.00 | — | 190,489 | — | ↗ |
| 2023-05-10 | Sakiris Spiro Kevin | Officer | C-Conversion | A | Common Stock | 2,399 | 5.80 | 13.9K | 4,745 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-2.1K
Shares Outstanding
645.8K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Harry Simeonidis Chief Executive Officer & President | 366.3K | — | 56.9K | — | — | 59.5K | 482.7K | 11.80% | ↗ |
| 2 | 2025 | Spiro Sakiris Chief Financial Officer | 269.0K | — | 49.1K | — | — | 45.4K | 363.5K | 13.51% | ↗ |
| 3 | 2024 | Harry Simeonidis Chief Executive Officer & President | 293.4K | 107.5K | — | — | — | 45.7K | 446.6K | 0.00% | ↗ |
| 4 | 2024 | Harry Simeonidis Chief Executive Officer and President | 293.4K | 54.1K | — | — | — | 45.7K | 393.2K | 0.00% | ↗ |
| 5 | 2024 | Spiro Sakiris Chief Financial Officer | 204.9K | 94.4K | — | — | — | 37.4K | 336.7K | 0.00% | ↗ |
| 6 | 2023 | Harry Simeonidis Chief Executive Officer and President | 276.1K | 53.4K | 32.5K | — | — | 34.7K | 396.7K | 8.20% | ↗ |
| 7 | 2023 | Spiro Sakiris Chief Financial Officer | 242.4K | 46.9K | 30.5K | — | — | 32.0K | 351.8K | 8.66% | ↗ |
| 8 | 2023 | Harry Simeonidis Chief Executive Officer and President Former President Asia Pacific, Sales and Marketing | 276.1K | — | 32.5K | — | — | 34.7K | 343.3K | 9.47% | ↗ |
| 9 | 2023 | Steven Boyages Former Interim Chief Executive Officer and current Chairman | 40.4K | — | 30.5K | — | — | 43.3K | 114.2K | 26.70% | ↗ |
| 10 | 2022 | Harry Simeonidis Chief Executive Officer and President Former President Asia Pacific, Sales and Marketing | 249.5K | 46.7K | — | — | — | 58.4K | 354.7K | 0.00% | ↗ |
| 11 | 2022 | Spiro Sakiris Chief Financial Officer | 210.5K | 42.1K | — | — | — | 39.9K | 292.5K | 0.00% | ↗ |
| 12 | 2022 | Steven Boyages Former Interim Chief Executive Officer and current Chairman | 29.0K | — | — | — | — | 42.4K | 71.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Harry Simeonidis | President & Chief Executive Officer | 425.7K | male |
| Spiro Kevin Sakiris | Chief Financial Officer | 314.4K | male |
| Anna Turkington | Vice President of Marketing | — | — |
| Callistus Sequeira | Vice President of Global Quality & Operations | — | — |
| Doug Heath | Vice President of Global Sales | — | male |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INBS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
